Vertex strikes yet another gene editing deal, this time with the “ultra-small” Crispr specialist Mammoth.
Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.
The group’s ambitions are startling, but it will need cash and collaborators to realise them.
The group hopes phase 2 data will back approval for its amyotrophic lateral sclerosis project AMX0035 after all.
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
An evolving virus demands innovative diagnostic technologies.
The entry of non-traditional funders – and the availability of non-traditional exits – has altered medtech, though probably only temporarily.
Mid-stage data with lenacapavir in treatment-naive patients justify pushing on; as for combos, Gilead is keeping its options open.
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.